Novartis Forges UC Berkeley Pact, sees drug hopefuls in three years


Novartis forges UC Berkeley pact, sees drug hopefuls in three years

Returns on R&D investment in the top 12 drug companies were only 3.7 percent in 2016, down from 10.1 percent in 2010, consultancy Deloitte has stated. As cost pressure is ratcheted up by insurers research costs are rising.

In August, Novartis won acceptance a first-of-its-kind gene-modifying immunotherapy for leukemia initiated by University of Pennsylvania scientists.

Reporting by John Miller and Paul Arnold

Old drugs such as Gleevec have lost patent protection, elevating Novartis’s urgency to find new medicines to rejuvenate sales to grow until next year.
Bradner said Novartis is looking for partnerships elsewhere.

For Nomura, the deep pockets of Novartis offer big opportunities.
Novartis gets reinforcements to help find elusive hotspots on the surfaces of proteins in which drugs can latch on and interrupt their role in preventing disease in enlisting Nomura’s lab.

Some two decades ago, its scientists teamed on Gleevec, the blood cancer drug that became the top seller of Novartis with Oregon Health & Science University researchers.

Drug companies have big incentives.
“Novartis is opening up their inner resources to us… allowing us to do things on a scale we couldn’t reach in an academic setting,” Nomura said in an email, including students will get an up-close look in the industrial side of research.

Novartis simply hired a chief digital officer to improve the way that it uses data in development and drug discovery.

ZURICH (Reuters) – Novartis’s NOVN.S research head expects an alliance with a University of California chemistry lab to generate drug candidates within three years as the Swiss company accelerates its hunt for new medicines.
Academic tie-ups have produced some of the biggest triumphs of Novartis.

“I anticipate within three years we will have identified appropriate candidates for definitive drug development.”

“Drug discovery is not best performed secretly, in private and in isolation,” he said. “I’m betting this group of blue sky investigators in academia, paired with our ruthless drug hunters at Novartis, will arrive at more creative, more brave and more definitive solutions than either group by themselves.”

Novartis expects Berkeley scientists the professor who runs the lab, including Daniel Nomura, will speed its search for the Achilles’ heels of diseases.
Novartis announced the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. It didn’t give financial details but said the multi-year deal aims “undruggable illnesses” like cancers that have eluded treatments.